
WhiteLab Genomics provides an AI-driven platform that speeds discovery and design of genomic therapies, reducing time and experimental workload. It combines graph knowledge technology, machine learning, and advanced computational biology to perform in-silico design and optimization of vectors, payloads, genotoxicity assessment, and experimental protocols. The platform supports modalities including AAV, lentiviral, and nanoparticle delivery and is used by biopharmaceutical companies and research institutions. WhiteLab's tools integrate into genomic R&D workflows to de-risk early development and accelerate candidate selection for downstream preclinical testing.

WhiteLab Genomics provides an AI-driven platform that speeds discovery and design of genomic therapies, reducing time and experimental workload. It combines graph knowledge technology, machine learning, and advanced computational biology to perform in-silico design and optimization of vectors, payloads, genotoxicity assessment, and experimental protocols. The platform supports modalities including AAV, lentiviral, and nanoparticle delivery and is used by biopharmaceutical companies and research institutions. WhiteLab's tools integrate into genomic R&D workflows to de-risk early development and accelerate candidate selection for downstream preclinical testing.
What they do: AI-driven platform (ALFRED AI) for design and optimization of genomic medicines (AAV, lentiviral, non-viral vectors, payloads, bioproduction)
Founded: 2019
Headquarters / presence: Paris, Boston, Montréal
Funding: $10M seed (Sep 12, 2022); pre-seed tied to Y Combinator (Mar 2022)
Investors / partners: Debiopharm Group, Omnes Capital, Y Combinator
Accelerating and de-risking genomic medicine R&D (gene and cell therapy development).
2019
Biotechnology
Pre-seed round associated with Y Combinator
10000000
Seed round announced Sep 12, 2022
“Debiopharm Group and Omnes Capital are lead investors; Y Combinator participated in earlier round”
| Company |
|---|
Company Name: Whitelab Genomics
Location: Paris
Employment Type: CDI (unspecified)
Salary: Not specified
Teleworking: Frequent teleworking
Gene Therapy Scientist
Job Description:
Our Gene Therapy Scientist will play a key role in supporting and coordinating the day-to-day non-clinical research activities across our programs. Reporting to the Head of Early-Preclinical Research, this role will involve contributing to the development of preclinical studies aimed at validating novel biological assets, such as viral and non-viral vectors, cell type-specific expression cassettes, new chimeric antigen receptors, and in-silico models. These contributions will support the advancement of WhiteLab's portfolio.
Non-Clinical Study Design & Execution
Cross-Functional Collaboration
Data Analysis & Reporting
Innovation & Continuous Improvement
We're Excited to Meet You If You…